Brokerages Anticipate Five Prime Therapeutics Inc (FPRX) Will Announce Earnings of -$1.07 Per Share

Equities analysts expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to post earnings of ($1.07) per share for the current quarter, according to Zacks. Four analysts have made estimates for Five Prime Therapeutics’ earnings. The lowest EPS estimate is ($1.50) and the highest is ($0.81). Five Prime Therapeutics reported earnings of ($0.63) per share during the same quarter last year, which would indicate a negative year over year growth rate of 69.8%. The firm is expected to report its next earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Five Prime Therapeutics will report full-year earnings of ($3.99) per share for the current financial year, with EPS estimates ranging from ($5.96) to ($3.35). For the next year, analysts expect that the firm will post earnings of ($2.95) per share, with EPS estimates ranging from ($3.67) to ($2.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Tuesday, February 26th. The biotechnology company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.20. Five Prime Therapeutics had a negative net margin of 281.64% and a negative return on equity of 44.55%.

FPRX has been the subject of a number of recent research reports. ValuEngine upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 20th. BidaskClub upgraded shares of Five Prime Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 22nd. Cowen reiterated a “buy” rating on shares of Five Prime Therapeutics in a report on Wednesday, February 27th. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Monday, January 21st. Finally, Wedbush upgraded shares of Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 target price for the company in a report on Thursday, January 17th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $24.29.

Shares of NASDAQ:FPRX traded down $0.30 during trading hours on Friday, reaching $13.40. The stock had a trading volume of 413,065 shares, compared to its average volume of 324,036. Five Prime Therapeutics has a 1 year low of $7.84 and a 1 year high of $19.95. The company has a market cap of $486.17 million, a PE ratio of -3.24 and a beta of 3.16.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp lifted its holdings in Five Prime Therapeutics by 0.5% in the 4th quarter. Northern Trust Corp now owns 425,775 shares of the biotechnology company’s stock valued at $3,959,000 after acquiring an additional 2,278 shares during the last quarter. Virtus ETF Advisers LLC increased its holdings in Five Prime Therapeutics by 17.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 31,427 shares of the biotechnology company’s stock worth $292,000 after buying an additional 4,603 shares during the last quarter. Quantamental Technologies LLC acquired a new position in Five Prime Therapeutics in the fourth quarter worth approximately $58,000. MetLife Investment Advisors LLC increased its holdings in Five Prime Therapeutics by 54.6% in the third quarter. MetLife Investment Advisors LLC now owns 30,852 shares of the biotechnology company’s stock worth $429,000 after buying an additional 10,895 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its holdings in Five Prime Therapeutics by 456.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,283 shares of the biotechnology company’s stock worth $124,000 after buying an additional 10,895 shares during the last quarter. 86.62% of the stock is owned by institutional investors.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Read More: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.